Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

1. The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose-related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occ...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: van Acker, S. A., Kramer, K., Grimbergen, J. A., van den Berg, D. J., van der Vijgh, W. J., Bast, A.
Format: Artigo
Langue:Inglês
Publié: 1995
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1908788/
https://ncbi.nlm.nih.gov/pubmed/7582554
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires